Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 20;20(1):87.
doi: 10.1186/s12968-018-0510-7.

Aminophylline shortage and current recommendations for reversal of vasodilator stress: an ASNC information statement endorsed by SCMR

Aiden Abidov  1 , Vasken Dilsizian  2 , Rami Doukky  3 , W Lane Duvall  4 , Christopher Dyke  5 , Michael D Elliott  6 , Fadi G Hage  7 , Milena J Henzlova  8 , Nils P Johnson  9 , Ronald G Schwartz  10 , Gregory S Thomas  11 , Andrew J Einstein  12
Affiliations
Review

Aminophylline shortage and current recommendations for reversal of vasodilator stress: an ASNC information statement endorsed by SCMR

Aiden Abidov et al. J Cardiovasc Magn Reson. .

Abstract

Pharmacologic reversal of serious or intolerable side effects (SISE) from vasodilator stress is an important safety and comfort measure for patients experiencing such effects. While typically performed using intravenous aminophylline, recurrent shortages of this agent have led to a greater need to limit its use and consider alternative agents. This information statement provides background and recommendations addressing indications for vasodilator reversal, timing of a reversal agent, incidence of observed SISE with vasodilator stress, clinical and logistical considerations for aminophylline-based reversal, and alternative non-aminophylline based reversal protocols.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Aiden Abidov, MD, PhD (Writing Committee Chair) - Research grant from NIH, GE Healthcare. Vasken Dilsizian, MD - Research grant from Siemens, GE Healthcare. Rami Doukky, MD, MSc - Research grant from Astellas. W. Lane Duvall, MD - Advisory board - Jubilant DraxImage, GE Healthcare. Christopher Dyke, MD – None. Michael D. Elliot, MD – None. Fadi Hage, MD - Research grant from Astellas, GE Healthcare. Milena J. Henzlova, MD, PhD – None. Nils P. Johnson, MD - Institution has licensing/consulting agreement with Boston Scientific for the start-minimum FFR algorithm. Frequently invited by academia/industry to speak at educational meetings/conferences on coronary physiology or cardiac PET and receive travel expenses and sometimes an honorarium, which I donate to my institution. Ronald G. Schwartz, MD, MS - Speakers Bureau – Astellas. Gregory S. Thomas, MD - Research grant to institution - Amgen and Novartis (CHF Trials), Speakers bureau - Astellas. Andrew J. Einstein, MD, PhD (Writing Committee Co-Chair)– Research grants to institution from NIH, Canon Medical Systems. Consultant, GE Healthcare.

Drs. Abidov, Dilsizian, Doukky, Duvall, Hage, Henzlova, Johnson, Schwartz, Thomas, and Einstein served as ASNC representatives. Drs. Dyke and Elliot served as SCMR representatives.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: stress, protocols, and tracers. J Nucl Cardiol. 2016;23:606–639. doi: 10.1007/s12350-015-0387-x. - DOI - PubMed
    1. Daya HA, Hage FG. Effect of aminophylline administration on the diagnostic yield of vasodilator myocardial perfusion imaging. J Nucl Cardiol. 2017;24:1579–1582. doi: 10.1007/s12350-016-0553-9. - DOI - PubMed
    1. Dilsizian V, Gewirtz H, Paivanas N, et al. Serious and potentially life threatening complications of cardiac stress testing: physiological mechanisms and management strategies. J Nucl Cardiol. 2015;22:1198–1213. doi: 10.1007/s12350-015-0141-4. - DOI - PubMed
    1. Rai M, Ahlberg AW, Marwell J, Chaudhary W, Savino JA, III, Alter EL, et al. Safety of vasodilator stress myocardial perfusion imaging in patients with elevated cardiac biomarkers. J Nucl Cardiol. 2017;24:724–734. doi: 10.1007/s12350-016-0448-9. - DOI - PubMed
    1. Doukky R, Rangel MO, Wassouf M, Dick R, Alqaid A, Morales Demori R. The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation. J Nucl Cardiol. 2013;20:205–213. doi: 10.1007/s12350-012-9654-2. - DOI - PubMed

MeSH terms